35 commercial payer policies list J2786. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
35 policies from 18 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J2786 |
|---|---|---|
| Cinqair (reslizumab) | Apr 1, 2024 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Cinqair (reslizumab) | Not recorded | Prior auth requiredInferred from policy title |
| Cinqair (reslizumab) | Not recorded | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Reslizumab (Cinqair) | Jul 1, 2020 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Reslizumab (Cinqair) | May 1, 2023 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Reslizumab (Cinqair) | Jun 1, 2021 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Reslizumab (Cinqair) | Jan 1, 2019 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Reslizumab (Cinqair) | May 1, 2022 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Reslizumab (Cinqair) | Aug 1, 2019 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Policy | Effective | Status of J2786 |
|---|---|---|
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Respiratory Interleukin-5 Inhibitor | Oct 1, 2026 | Covered |
| Respiratory Interleukins – Community Plan Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Interleukin-5 (IL-5) Antagonist (e.g., Cinqair, Exdensur, Nucala) and IL-5 Receptor Antagonist (e.g., Fasenra) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Interleukin-5 (IL-5) Antagonist (e.g., Cinqair, Exdensur) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Reslizumab | Nov 15, 2025 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Reslizumab | Nov 15, 2025 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Reslizumab | Nov 15, 2025 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Reslizumab | Nov 15, 2025 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Interleukin-5 (IL-5) Antagonist (e.g., Cinqair, Exdensur, Nucala) and IL-5 Receptor Antagonist (e.g., Fasenra) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Interleukin-5 (IL-5) Antagonist (e.g., Cinqair, Exdensur) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Respiratory Interleukin-5 Inhibitor | Oct 1, 2026 | Covered |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Reslizumab (e.g., Cinqair) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| CINQAIR (RESLIZUMAB) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Reslizumab (Cinqair) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Cinqair (Reslizumab) | Nov 1, 2025 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Reslizumab (Cinqair); CP.PHAR.223 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Monoclonal Interleukin-5 Antagonists [mepolizumab (Nucala), reslizumab (Cinqair), and benralizumab (Fasenra)] | Sep 11, 2020 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| 00511 reslizumab (Cinqair) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Cinqair (reslizumab) Listed in Moda Health's provider indexes for Oregon, Alaska, Idaho, Texas. The document does not establish the member's state or line of business. | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Respiratory Interleukin-5 Inhibitor | Oct 1, 2026 | Covered |